Retinoic acid receptor a agonists for the treatment of Alzheimer's disease (360G-Wellcome-084286_Z_07_C)

£354,795

Retinoic acid receptor a agonists for the treatment of Alzheimer's disease. The current licensed treatments for Alzheimer's disease improve the symptoms that people experience but do not alter the progression of the underlying disease changes in the brain.Most of the attempts to develop new treatments have focused on altering deposits of the amyloid protein in the brain, but despite more than a decade of intensive research this has still not yielded any new therapies in the clinic. The studies of Dr Jonathan Corcoran of King's College London highlight a specific retinoic acid receptor (RAR)a agonist as a novel and exciting target for the development of new treatments. This agonist has two mechanisms of action - it regulates amyloid deposits in the brain and also plays a key role in the survival of neurons. In their project they will generate novel RARa agonists for the treatment of Alzheimer's disease.

Where is this data from?

This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.

Grant Details

Amount Awarded 354795
Applicant Surname Corcoran
Approval Committee Seeding Drug Discovery Committee
Award Date 2010-01-31T00:00:00+00:00
Financial Year 2009/10
Grant Programme: Title Seeding Drug Discovery Award
Internal ID 084286/Z/07/C
Lead Applicant Prof Jonathan Corcoran
Partnership Value 354795
Planned Dates: End Date 2011-12-30T00:00:00+00:00
Planned Dates: Start Date 2010-01-31T00:00:00+00:00
Recipient Org: Country United Kingdom
Region Greater London